An Open-Label Clinical Study to Evaluate the Pharmacokinetics of MK-0616 Following Administration of a Single Dose to Participants With Moderate Renal Impairment
Latest Information Update: 01 Oct 2024
Price :
$35 *
At a glance
- Drugs Enlicitide decanoate (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 19 May 2023 Status changed from active, no longer recruiting to completed.
- 27 Apr 2023 Planned End Date changed from 14 May 2023 to 3 May 2023.
- 27 Apr 2023 Planned primary completion date changed from 14 May 2023 to 3 May 2023.